September 27, 2023 11:16 AM EDT

Théa won't buy ProQR's ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in October

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

ProQR’s failed divestiture: Laboratoires Théa scrapped plans to buy ProQR Therapeutics’ late-stage ophthalmic pipeline after announcing a deal in early …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Théa won't buy ProQR's ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in October

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Théa won't buy Pro­QR's oph­thalmic as­sets; Im­muno­vant’s $130M of­fer­ing; In­ozyme to start piv­otal study in Oc­to­ber

Deputy Editor

Senior Reporter

News Reporter

Sign up to read this article for free.

Théa won't buy ProQR's ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in October